<DOC>
	<DOCNO>NCT02559791</DOCNO>
	<brief_summary>The steroid spar effect anti interleukin ( IL-5 ) monoclonal antibody proven , effectiveness subcutaneous ( SC ) compare intravenous ( IV ) administration drug suppress airway eosinophilia still debate . As part previous study , 100mg mepolizumab administer subcutaneously group subject prednisone-dependent eosinophilic asthma . Despite intervention , 50 % subject ( 15 patient participate study ) persistently elevate sputum eosinophil count . The 15 patient invited participate current study , provide informed consent , receive 2 monthly dos placebo , follow 4 monthly dos IV reslizumab . The primary outcome blood sputum eosinophil , secondary outcome include sputum blood Innate lymphoid cell-2 ( ILC2 ) cell , cluster differentiation 4 ( CD4+ ) cell , cluster differentiation-8 ( CD8+ ) cell , cluster differentiation-34 ( CD34+ ) , Eosinophil-Basophil cluster cell ( Eo/B progenitor cell ) , force expire volume 1 second ( FEV1 ) , asthma control questionnaire ( ACQ ) number eosinophilic exacerbation . Measurements outcomes do placebo , placebo IV reslizumab . This study design determine whether IV reslizumab effective suppress airway eosinophilia prednisone-dependent patient .</brief_summary>
	<brief_title>Anti-Interleukin-5 ( IL5 ) Monoclonal Antibody ( MAb ) Prednisone-dependent Eosinophilic Asthma</brief_title>
	<detailed_description>Study design Blinded placebo-controlled sequential clinical trial 4 monthly dos intravenously administer reslizumab . The study include two period : Period 1 : After establish minimum dose prednisone observe sputum eosinophils ≥3 % blood eosinophil ≥300/µL , subject receive 2 infusion ( monthly ) match placebo . Period 2 : All subject receive 4 infusion ( monthly ) reslizumab 3mg/kg . Methods 15 patient ( sputum eosinophil ≥3 % blood eosinophil ≥300/µL ) previously treat S/C100 mg mepolizumab least 6 month , last dose least 4 month enter study , invite participate study . Since discontinue mepolizumab , patient would re-established maintenance dose daily prednisone + high dos inhale corticosteroid ( ICS ) long act beta agonist ( LABA ) . Baseline measurement blood sputum eosinophil , spirometry , symptom ( ACQ ) , immune cell blood sputum ( ILC2 cell , CD4 + cell , CD8+ cell , CD34+ Eo/B progenitor cell ) enumerate flow cytometry , measure local autoimmunity , use establish protocols start Period 1 ( baseline measurement ) . They receive 2 infusion placebo monthly interval , measurement repeat end Period 1 ( post-placebo measurement ) . The subject receive 4 infusion 3 mg/kg reslizumab monthly interval . At end 4 month , measurement repeat ( post-reslizumab measurement ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Pulmonary Eosinophilia</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>1 . Informed consent Prior beginning study , patient must willing fully capable provide write informed consent . 2 . Prednisonedependent eosinophilic asthma Documented evidence asthma : FEV1 reversibility 12 % 200 ml 200400 microgram SABA . Or Methacholine challenge test &lt; 8mg/ml . Documented history persistent eosinophilia ( sputum eosinophil ≥3 % and/or blood eosinophil ≥300/µL ) despite maintenance treatment systemic glucocorticoid ( 5 35 mg per day prednisone equivalent ) enter study . 3 . Previous treatment 100 mg mepolizumab administer subcutaneously least 6 month , last dose least 4 month enter study 4 . Sputum eosinophils ≥3 % blood eosinophil ≥300/µL visit 1 ( screen visit ) . 5 . Age 18 75 year . 6 . Male eligible female subject : To eligible entry study , female childbearing potential ( premenopausal woman permanently sterilize mean hysterectomy , bilateral oophorectomy , bilateral salpingectomy ) must commit consistent correct use highly effective method birth control ( true sexual abstinence , vasectomize sexual partner , Implanon , female tubal occlusion , Intrauterine device ( IUD ) , Depo provera injection , oral contraceptive pill Nuvaring ) duration trial 3 month last study drug administration . A serum pregnancy test require female initial Baseline Visit ( Visit 1 ) . In addition , urine pregnancy test perform female prior enrollment , schedule study visit prior injection investigational product , Followup Visit . 7 . Male subject sexually active must agree use double barrier method contraception ( condom spermicide ) first dose study drug 3 month last dose study drug . 1 . Currently receive another monoclonal antibody 2 . Currently receive investigational drug immunosuppressive medication 3 . Known hypersensitivity Reslizumab product excipients . 4 . Intolerance , hypersensitivity , insensitivity neutralize antibody mepolizumab . 5 . Malignancy within last 2 year 6 . Any comorbidity investigator believe contraindication . This include limited respiratory ( eg . COPD , pulmonary fibrosis , EGPA , ABPA ) , cardiovascular , gastrointestinal , hematological , neurological , immunological , musculoskeletal , renal , infectious , neoplastic inflammatory condition may place safety subject risk duration study , influence result study interpretation , prevent patient complete entire duration study . 7 . Current pregnancy lactation 8 . Current smoker exsmoker smoke history great 20 pack year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Reslizumab</keyword>
	<keyword>Eosinophils</keyword>
	<keyword>Asthma</keyword>
	<keyword>Airway inflammation</keyword>
	<keyword>Prednisone</keyword>
</DOC>